OI Ljubljana
Sl

Clinical studies

The goal of clinical studies is to evaluate and introduce new treatment of cancer. The clinical trial are conducted in the frame or under auspicies of international association, or as an EU funded projects, sponsored by pharmaceutical companies or are the results of our own knowledge.

Clinical studies recruiting patients

Breast cancer

CodeResearch titlePrincipal InvestigatorConsents informed
KATE3 A randomized, multicenter, double-blind, placebo-contolled phase III study of the efficacy and safety of trastumab emtasine in combination with atezolizumab or placebo in patients with HER2 positive locally advanced or metastatic breast cancer who have received trastuzumab-(+/- pertuzmab) and taxane-based therapy Domen Ribnikar KATE3.pdf
EPIK-B3 EPIK-B3: A Phase III, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation Simona Borstnar
IMMUNOBREAST THE USE OF AUTOLOGOUS IMMUNOHYBRIDOMAS IN TREATMENT OF PATIENTS WITH STAGE II AND III TRIPLE NEGATIVE BREAST CANCER Simona Borstnar
LIDERA A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR−POSITIVE, HER2-NEGATIVE EARLY BREAST CANCER Simona Borstnar
PALMIRA INTERNATIONAL, MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE II CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF CONTINUATION OF PALBOCICLIB IN COMBINATION WITH SECOND-LINE ENDOCRINE THERAPY IN HORMONE RECEPTOR-POSITIVE/HER2-NEGATIVE ADVANCED BREAST CANCER PATIENTS WHO HAVE ACHIEVED CLINICAL BENEFIT DURING FIRST-LINE PALBOCICLIB-BASED TREATMENT Erika Matos

Urinary tract cancer

Head and neck cancers

CodeResearch titlePrincipal InvestigatorConsents informed
SmartGene Treatment of head and neck skin cancers with interleukin 12 gene electrotransfer Gregor Sersa, Primoz Strojan

 

 

© 2019 - Institute of Oncology Ljubljana
Accessibility(CTRL+F2)
color contrast
text size
highlighting content
zoom in